■呼吸道感染引起的死亡是当今世界上主要的死亡原因之一。疏风解毒胶囊(SFJDC)是一种中药,已在临床上广泛用于冠状病毒病2019(COVID-19),甲型H1N1流感病毒肺炎等疾病。其药理作用是抑制炎症,提高机体清除病毒的能力。然而,SFJDC治疗病毒性肺炎的机制,尤其是其对肺组织炎症免疫微环境的影响尚不清楚。
■以H1N1流感病毒肺炎小鼠为模型,通过死亡保护来验证SFJDC的功效,肺指数,病毒载量,肺组织HE染色。通过多分析物免疫测定研究了肺组织中炎性细胞因子和趋化因子的水平。用血惯例检测外周血细胞数目和比例。流式细胞术和免疫荧光法检测肺组织中浸润免疫细胞的百分比。
■SFJDC(2.2g/kg·d-1和1.1g/kg·d-1)提高成活率(P<0.01,P<0.05),延长了小鼠的生存期,减轻肺组织病理学损伤(P<0.01)。SFJDC(2.2g/kg·d-1、1.1g/kg·d-1和0.055g/kg·d-1)增加体重(P<0.01,P<0.05),改进的活动状态,肺指数降低(P<0.01,P<0.05),病毒载量降低(P<0.01)。SFJDC(2.2g/kg·d-1和1.1g/kg·d-1)降低白细胞介素-1β(IL-1β),白细胞介素-18(IL-18),肿瘤坏死因子α(TNF-α),单核细胞趋化蛋白(MCP),趋化因子(C-X-C基序)配体1(CXCL1)(P<0.01,P<0.05),和SFJDC(2.2g/kg·d-1)升高IL-10水平(P<0.05)以调节炎症.SFJDC(2.2g/kg·d-1)增加CD4+T细胞百分比(P<0.01),CD8+T细胞(P<0.05),B细胞(P<0.05),F4/80+巨噬细胞减少(P<0.05)。
■我们的发现表明,SFJDC可以抑制炎症和肺损伤,同时维持T和B细胞介导的适应性免疫反应的功能,并促进病毒的清除,从而治疗甲型H1N1流感病毒引起的肺炎。
UNASSIGNED: Death caused by respiratory tract infection is one of the leading causes of death in the world today. Shufeng Jiedu Capsule (SFJDC) is a traditional Chinese medicine that has been widely used clinically for coronavirus disease 2019 (COVID-19), H1N1 influenza virus pneumonia and other diseases. Its pharmacological effect is to inhibit inflammation and improve the body\'s ability to clear viruses. However, the mechanism of SFJDC in the treatment of viral pneumonia, especially its effect on the inflammatory-immune microenvironment of lung tissue remains unclear.
UNASSIGNED: Mice with H1N1 influenza virus pneumonia were used as a model to verify the efficacy of SFJDC through death protection, lung index, viral load, and HE staining of lung tissue. The levels of inflammatory cytokines and chemokines in lung tissue were investigated by multi-analyte immunoassay. The number and proportion of cells in peripheral blood were detected by blood routine. The percentage of infiltrating immune cells in lung tissue was detected by flow cytometry and immunofluorescence.
UNASSIGNED: SFJDC (2.2 g/kg·d-1 and 1.1 g/kg·d-1) increased survival rate (P<0.01, P<0.05), prolonged the survival period of mice, and alleviated the histopathological damage in lung (P<0.01). SFJDC (2.2 g/kg·d-1, 1.1 g/kg·d-1 and 0.055 g/kg·d-1) increased body weight(P<0.01, P<0.05), improved activity status, reduced the lung index (P<0.01, P<0.05) and viral load (P<0.01). SFJDC (2.2 g/kg·d-1 and 1.1 g/kg·d-1) reduced interleukin-1β (IL-1β), interleukin-18(IL-18), tumour necrosis factor α (TNF-α), monocyte chemoattractant protein (MCP), chemokine (C-X-C motif) ligand 1 (CXCL1) (P<0.01, P<0.05), and SFJDC (2.2 g/kg·d-1) increased IL-10 levels (P<0.05) to regulate inflammation. SFJDC (2.2 g/kg·d-1) increased the percentages of CD4+ T cells (P<0.01), CD8+ T cells (P<0.05), and B cells(P<0.05), and decreased F4/80+ macrophages (P<0.05).
UNASSIGNED: Our findings indicated that SFJDC could inhibit inflammation and lung injury while maintaining the function of the adaptive immune response mediated by T and B cells, and promote the clearance of the virus, thereby treating influenza A (H1N1) virus-induced pneumonia.